Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...
Streetwise Reports | June 2, 2020 |

Buzz on the Bullboards: On the verge of recession? These stocks could be a lifesaver

Welcome back to Buzz on the Bullboards. It has been a busy week for markets and investors alike. Each new twist has sent currencies and commodities bouncing up and down, and no one can figure out...
Stockhouse Editorial | June 9, 2022 |

US Biopharma to Launch Phase 3 Trial in Bacterial Vaginosis

Daré Bioscience's study, its prospects and the indication's U.S. market opportunity are discussed in a ROTH Capital Partners report. In a May 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi reviewed why the outlook is positive for Daré Bioscience In...
Streetwise Reports | May 21, 2020 |

Significant Size, Grade, Returns

Steve Todoruk of Sprott USA , and the 2019 Pezim Award winner sits down with Maurice Jackson of Proven and Probable to discuss the Significant New Discoveries and the impact on your portfolio. Mr. Todoruk has a proven pedigree of identifying promising new...
Maurice Jackson | March 13, 2020 |

Klondike Golden Moments

Foreword: This tale grew from a chance nugget discovery along the shore of a humble Yukon creek carving through the remote Territory and became the great history of the Klondike Gold Rush. Join author James Kwantes as he touches down in the Yukon with 12 exciting stories and c...
James Kwantes | August 15, 2019 |

Dec 12th 2019, Silver Chartbook – Aggressive participation, why?

Aggressive participation, why? As much as we use a technical analysis dominated approach toward the markets, it would be foolish to not have those views guided by fundamentals. It is at this point in time a true confluence point of world wide events that drive o...
Korbinian Koller | December 12, 2019 |

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. Today, in a late-breaking oral presentation at the European Soc...
Streetwise Reports | September 30, 2019 |

Investors Snap Up Crocs Shares On Positive Q3 Earnings and Raised Yearly Outlook

Shares of Crocs Inc. traded 15% higher at times today reaching a 52-week intraday high price after the firm reported Q3/19 earnings and raised its FY/19 guidance. Early this morning Niwot, Colo. based Crocs Inc. (CROX:NASDAQ), which claims to be a top-10 world leade...
Streetwise Reports | October 31, 2019 |

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a N...
Streetwise Reports | November 20, 2019 |

Immunomedics Shares Double as Phase 3 Breast Cancer Trial Achieves 'Compelling' Efficacy Data

Shares of Immunomedics opened 117% higher after the company reported that it has stopped its Phase 3 ASCENT study of sacituzumab govitecan after recording "compelling evidence of efficacy" in heavily pretreated patients with metastatic triple-negative breast cancer. ...
Streetwise Reports | April 7, 2020 |
1 2 3 4 5 6 7 8 9 10 ...